Prostate MRI has become central to the diagnostic pathway for suspected prostate cancer in the UK, reshaping decisions on biopsy, staging and subsequent management. Guidance from professional bodies recommends MRI before biopsy to improve detection of clinically significant disease and reduce unnecessary procedures. Despite this shared framework, day-to-day practice varies between centres in how imaging is performed, reported and integrated into clinical pathways. A national survey of UK consultant radiologists reporting prostate MRI provides a detailed picture of current practice across NHS Trusts, reflecting recent changes in workforce, technology and clinical expectations. The findings highlight areas of consistency, such as universal pre-biopsy MRI, alongside variation in protocols, scoring systems and staging strategies.
MRI Protocols and Patient Preparation
MRI protocols for suspected localised prostate cancer show notable variation across UK Trusts. Most centres use multiparametric MRI, incorporating T2-weighted imaging, diffusion-weighted imaging and dynamic contrast-enhanced sequences, while a smaller proportion employ biparametric MRI without contrast. The balance between these approaches reflects differing views on the value of contrast, efficiency and image quality. Radiologists using multiparametric MRI expressed mixed willingness to switch to biparametric protocols if future guidance recommended such a change, indicating ongoing debate rather than consensus.
Must Read: AI Prostate MRI Misses Specificity
Patient preparation before prostate MRI is inconsistent. Some Trusts advise bowel emptying or abstention from ejaculation, while others provide no specific instructions. Anti-spasmodic medication is routinely administered in the majority of centres, most commonly hyoscine butylbromide delivered intravenously or intramuscularly, although a substantial minority do not use medication at all. Beyond core sequences, many Trusts include additional imaging, such as large field-of-view pelvic sequences or upper abdominal imaging, extending scan time and reporting workload. These differences underline the absence of a unified national approach to preparation and protocol design.
Reporting Standards and Scoring Systems
Reporting practices also vary, particularly in the use of scoring systems to convey cancer risk. Radiologists employ the Prostate Imaging–Reporting and Data System score, a Likert score or both, with no single approach dominating. The concurrent use of two five-point systems within the same clinical environment reflects differing interpretations of national guidance and personal preference. Some radiologists allow clinical factors to influence imaging scores, introducing further variability in how risk is communicated.
Awareness of additional scoring systems designed to support quality assurance, active surveillance or post-treatment assessment is widespread, but routine use remains limited. The prostate image quality score is recognised by many radiologists but applied infrequently in daily practice, often viewed as time consuming or of limited practical value when image quality issues cannot be remedied. Other systems aimed at monitoring disease progression or treatment effects are more commonly used in university teaching hospitals, suggesting an association with subspecialist expertise and academic environments. Overall, the findings point to a fragmented reporting landscape with potential implications for clarity and consistency in multidisciplinary decision-making.
Biopsy Pathways and Staging Approaches
All surveyed Trusts perform prostate MRI before biopsy, marking a clear shift from earlier practice and aligning imaging firmly at the start of the diagnostic pathway. Transperineal biopsy has become the dominant technique, usually performed under local anaesthetic and most often by urologists or specialist nurses. Radiologists and radiographers also contribute in some centres, reflecting evolving professional roles within the NHS. Targeted biopsy is standard practice, predominantly using cognitive targeting rather than MRI-ultrasound fusion.
Staging pathways for high and very high-risk disease show considerable variation. Most Trusts rely on computed tomography combined with bone scintigraphy, while a smaller proportion use prostate specific membrane antigen positron emission tomography with computed tomography. Access to advanced imaging is uneven, with university teaching hospitals more likely to offer positron emission tomography. No centres reported routine use of whole-body MRI for staging. These differences highlight ongoing challenges in aligning diagnostic capability with emerging recommendations and resource availability.
Current prostate MRI practice in the UK demonstrates both maturity and variability. Universal adoption of pre-biopsy MRI and widespread use of transperineal biopsy indicate substantial progress in standardising key elements of care. At the same time, differences in imaging protocols, reporting approaches and staging strategies reveal opportunities for greater alignment. Addressing variation could support more consistent communication, optimise resource use and help ensure equitable access to high-quality prostate cancer diagnostics across the UK.
Source: British Journal of Radiology
Image Credit: iStock
